-transparent.png){kind=logo}
Patients with systemic lupus erythematosus are at increased risk for premature atherosclerosis. We examined one possible etiologic factor, dyslipoproteinemia, both before and after corticosteroid therapy. We identified 2 distinct patterns of dyslipoproteinemia. One is attributable to active disease; the other is attributable, in part, to corticosteroid therapy. The dyslipoproteinemia of active disease consists of depressed high density lipoprotein cholesterol and apoprotein A-I with elevated very low density lipoprotein cholesterol and triglyceride, while the dyslipoproteinemia after corticosteroid therapy consists of increased total cholesterol, very low density lipoprotein cholesterol, and triglyceride. The possible pathophysiologic mechanisms responsible for these patterns, as well as the possible roles in premature atherosclerosis seen in systemic lupus erythematosus patients, are discussed.
N T Ilowite, and
P Samuel, and
E Ginzler, and
M S Jacobson
December 2004,
Current rheumatology reports,
N T Ilowite, and
P Samuel, and
E Ginzler, and
M S Jacobson
January 2008,
Autoimmunity reviews,
N T Ilowite, and
P Samuel, and
E Ginzler, and
M S Jacobson
September 1987,
The American journal of medicine,
N T Ilowite, and
P Samuel, and
E Ginzler, and
M S Jacobson
July 1995,
The Journal of rheumatology,
N T Ilowite, and
P Samuel, and
E Ginzler, and
M S Jacobson
January 2004,
Lupus,
N T Ilowite, and
P Samuel, and
E Ginzler, and
M S Jacobson
November 2013,
Lupus,
N T Ilowite, and
P Samuel, and
E Ginzler, and
M S Jacobson
June 1987,
The Journal of rheumatology. Supplement,
N T Ilowite, and
P Samuel, and
E Ginzler, and
M S Jacobson
September 2009,
Georgian medical news,
N T Ilowite, and
P Samuel, and
E Ginzler, and
M S Jacobson
June 2007,
The Journal of rheumatology,
N T Ilowite, and
P Samuel, and
E Ginzler, and
M S Jacobson
February 1994,
Rheumatic diseases clinics of North America,
